New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer

Launched by SUN YAT-SEN MEMORIAL HOSPITAL OF SUN YAT-SEN UNIVERSITY · Nov 2, 2023

Keywords

ClinConnect Summary

1. The clinicopathological data of patients newly diagnosed with high-grade serous ovarian cancer in Sun Yat-sen Memorial Hospital were collected and screened.
2. Statistical analysis of hematological indicators that may be related to inflammation before platinum-based therapy in patients who met the inclusion criteria, including but not limited to: Absolute white blood cell count, absolute neutrophil count, absolute lymphocyte count, absolute monocyte count, platelet count, hemoglobin and fibrinogen were calculated. NLR, MLR, PLR, FLR and SII were calculated, and the correlation between th...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. confirmed diagnosis of HGSOC by two experienced pathologists;
• • 2. clinical stage III-IV according to the 2018 International Federation of Gynecology and Obstetrics (FIGO) guideline;
• • 3. Eastern Cooperative Oncology Group (ECGO) performance status of 0 to 1;
• • 4. no prior anti-cancer therapy;
• • 5. received ≥ 3 cycles of platinum-based NACT followed by IDS;
• • 6. complete pretreatment blood test results and clinical and imaging data.
• Exclusion Criteria:
• • 1. other pathological types;
• • 2. without NACT or IDS;
• • 3. incomplete pretreatment data;
• • 4. lost to follow-up.